[go: up one dir, main page]

WO2009132928A3 - Molecular markers for cancer prognosis - Google Patents

Molecular markers for cancer prognosis Download PDF

Info

Publication number
WO2009132928A3
WO2009132928A3 PCT/EP2009/054034 EP2009054034W WO2009132928A3 WO 2009132928 A3 WO2009132928 A3 WO 2009132928A3 EP 2009054034 W EP2009054034 W EP 2009054034W WO 2009132928 A3 WO2009132928 A3 WO 2009132928A3
Authority
WO
WIPO (PCT)
Prior art keywords
high risk
risk
low risk
outcome
gene expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/054034
Other languages
French (fr)
Other versions
WO2009132928A2 (en
Inventor
Udo Stropp
Christian VON TÖRNE
Mathias Gehrmann
Ralf Kronenwett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Siemens Healthcare Diagnostics Inc
Original Assignee
Siemens Healthcare Diagnostics GmbH Germany
Siemens Healthcare Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens Healthcare Diagnostics GmbH Germany, Siemens Healthcare Diagnostics Inc filed Critical Siemens Healthcare Diagnostics GmbH Germany
Publication of WO2009132928A2 publication Critical patent/WO2009132928A2/en
Publication of WO2009132928A3 publication Critical patent/WO2009132928A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention is predicated on a method of identification of a panel of genes informative for the outcome of disease which can be combined into an algorithm for a prognostic or predictive test. The algorithm makes use of gene expression data from biological samples and classifies patients as having a high risk or low risk, e.g. in cancer patients a metastasis bad outcome or good outcome group. Reference patterns of gene expression are obtained for the high risk and low risk groups, respectively. A sample of an unknown patient is analyzed and classified as belonging to the high risk or low risk group, respectively, depending on correlation to the high risk reference pattern or low risk reference pattern.
PCT/EP2009/054034 2008-05-02 2009-04-03 Molecular markers for cancer prognosis Ceased WO2009132928A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08008371 2008-05-02
EP08008371.0 2008-05-02

Publications (2)

Publication Number Publication Date
WO2009132928A2 WO2009132928A2 (en) 2009-11-05
WO2009132928A3 true WO2009132928A3 (en) 2009-12-23

Family

ID=40875041

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/054034 Ceased WO2009132928A2 (en) 2008-05-02 2009-04-03 Molecular markers for cancer prognosis

Country Status (1)

Country Link
WO (1) WO2009132928A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010321829B2 (en) * 2009-11-23 2015-07-30 Genomic Health, Inc. Methods to predict clinical outcome of cancer
FI20105252A0 (en) 2010-03-12 2010-03-12 Medisapiens Oy METHOD, ORGANIZATION AND COMPUTER SOFTWARE PRODUCT FOR ANALYZING A BIOLOGICAL OR MEDICAL SAMPLE
HUE030164T2 (en) * 2010-03-31 2017-05-29 Sividon Diagnostics Gmbh Method for breast cancer recurrence prediction under endocrine treatment
WO2013165598A1 (en) * 2012-04-30 2013-11-07 The Research Foundation For Suny Cancer blood test using bc200 rna isolated from peripheral blood for diagnosis and treatment of invasive breast cancer
ES2654469T3 (en) 2013-02-01 2018-02-13 Sividon Diagnostics Gmbh Procedure for predicting the benefit of the inclusion of taxane in a chemotherapy regimen in patients with breast cancer
EP3679160A4 (en) 2017-09-08 2021-05-19 Myriad Genetics, Inc. METHOD OF USING BIOMARKERS AND CLINICAL VARIABLES TO PREDICT THE INTEREST OF CHEMOTHERAPY

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158399A1 (en) * 1995-03-03 2003-08-21 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
WO2005033699A2 (en) * 2003-10-03 2005-04-14 Ncc Technology Ventures Pte Limited Materials and methods relating to breast cancer classification
WO2006136314A1 (en) * 2005-06-23 2006-12-28 Siemens Medical Solutions Diagnostics Gmbh Magnetic particles with a closed ultrathin silica layer, method for the production thereof and their use
WO2007030611A2 (en) * 2005-09-09 2007-03-15 The Board Of Regents Of The University Of Texas System A calculated index of genomic expression of estrogen receptor (er) and er related genes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158399A1 (en) * 1995-03-03 2003-08-21 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
WO2005033699A2 (en) * 2003-10-03 2005-04-14 Ncc Technology Ventures Pte Limited Materials and methods relating to breast cancer classification
WO2006136314A1 (en) * 2005-06-23 2006-12-28 Siemens Medical Solutions Diagnostics Gmbh Magnetic particles with a closed ultrathin silica layer, method for the production thereof and their use
WO2007030611A2 (en) * 2005-09-09 2007-03-15 The Board Of Regents Of The University Of Texas System A calculated index of genomic expression of estrogen receptor (er) and er related genes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GLINSKY G V ET AL: "Classification of human breast cancer using gene expression profiling as a component of the survival predictor algorithm", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 10, no. 7, 1 April 2004 (2004-04-01), pages 2272 - 2283, XP002309961, ISSN: 1078-0432 *
SORLIE T ET AL: "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 98, no. 19, 11 September 2001 (2001-09-11), pages 10869 - 10874, XP002215483, ISSN: 0027-8424 *
VEER VAN 'T L J ET AL: "Gene expression profiling predicts clinical outcome of breast cancer", NATURE, NATURE PUBLISHING GROUP, LONDON, UK, vol. 415, no. 6871, 31 January 2002 (2002-01-31), pages 530 - 536, XP002259781, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
WO2009132928A2 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
JP7717608B2 (en) Methods and systems for high-depth sequencing of methylated nucleic acids
Dyrskjøt et al. Identifying distinct classes of bladder carcinoma using microarrays
Tsoucas et al. Recent progress in single-cell cancer genomics
Fan et al. Methods for genome-wide DNA methylation analysis in human cancer
KR20240018667A (en) Cancer detection and classification using methylome analysis
Gnanapragasam Unlocking the molecular archive: the emerging use of formalin‐fixed paraffin‐embedded tissue for biomarker research in urological cancer
WO2009132928A3 (en) Molecular markers for cancer prognosis
NZ593225A (en) Gene expression markers (CMYC and Ki-67) for colorectal cancer prognosis
WO2011116380A2 (en) Hybrid model for the classification of carcinoma subtypes
CN110706749A (en) Cancer type prediction system and method based on tissue and organ differentiation hierarchical relation
WO2008039071A3 (en) High-throughput diagnostic testing using arrays
Chung et al. Gene expression profiling of papillary thyroid carcinomas in Korean patients by oligonucleotide microarrays
CN106868204A (en) A kind of biomarker for sdenocarcinoma of stomach diagnosis
CN102782151A (en) Circulating miRNA as non-invasive markers for diagnosis and staging in prostate cancer
CN107729718A (en) A kind of mammary gland carcinogenesis correlated characteristic genetic screening methodology
Osunkoya et al. Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis
WO2015117210A1 (en) Process, apparatus or system and kit for classification of tumor samples of unknown and/or uncertain origin and use of genes of the group of biomarkers
WO2008104984A3 (en) Diagnosis and prognosis of various types of cancers
CN111100863B (en) Application of fingerprint spectrum composed of small RNA in diagnosis and treatment of lung cancer
WO2010046530A8 (en) Methods and uses involving genetic aberrations of nav3 and aberrant expression of multiple genes
EP2906713A1 (en) Micro-rna biomarkers for prostate cancer
EP3983561A1 (en) Dna methylation based high resolution characterization of microbiome using nanopore sequencing
CN108728439A (en) The finger-print of tiny RNA composition and its application in Diagnosis of Bladder
CN109706146A (en) Application of the finger-print of tiny RNA composition in the Cancerous Pleural Effusion diagnosing and treating of people
HK40052606A (en) Methods and systems for high-depth sequencing of methylated nucleic acid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09737972

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09737972

Country of ref document: EP

Kind code of ref document: A2